相似文献
1
Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.
Breast Cancer Res. 2003;5(2):96-100. doi: 10.1186/bcr574. Epub 2003 Feb 3.
2
3
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Semin Oncol. 1999 Aug;26(4 Suppl 12):78-83.
4
Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
Drugs. 2002;62(1):209-43. doi: 10.2165/00003495-200262010-00008.
5
Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Semin Oncol. 2001 Dec;28(6 Suppl 18):43-7.
6
From HER2 to herceptin.
Curr Med Res Opin. 2001;17(1):51-9. doi: 10.1185/0300799039117027.
7
Trastuzumab in metastatic breast cancer.
Eur J Gynaecol Oncol. 2006;27(3):247-9.
8
Her2-positive breast cancer: herceptin and beyond.
Eur J Cancer. 2008 Dec;44(18):2806-12. doi: 10.1016/j.ejca.2008.09.013. Epub 2008 Nov 18.
9
Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Am J Ther. 2005 May-Jun;12(3):243-53.
10
Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Oncology. 2001;61 Suppl 2:14-21. doi: 10.1159/000055397.
引用本文的文献
1
Long non-coding RNAs regulation of therapeutic resistance.
Cancer Drug Resist. 2019 Sep 19;2(3):550-567. doi: 10.20517/cdr.2019.58. eCollection 2019.
2
Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies.
Cancers (Basel). 2020 Nov 11;12(11):3327. doi: 10.3390/cancers12113327.
3
Trastuzumab Targeted Neratinib Loaded Poly-Amidoamine Dendrimer Nanocapsules for Breast Cancer Therapy.
Int J Nanomedicine. 2020 Jul 30;15:5433-5443. doi: 10.2147/IJN.S256898. eCollection 2020.
4
Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
MAbs. 2018 May/Jun;10(4):547-571. doi: 10.1080/19420862.2018.1440170. Epub 2018 Mar 14.
5
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016.
6
Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive.
Mol Cell Biol. 2016 Jan 11;36(7):1050-63. doi: 10.1128/MCB.00652-15.
7
MicroRNA and HER2-overexpressing cancer.
Microrna. 2013;2(2):137-47. doi: 10.2174/22115366113029990011.
8
Development of an innovative 3D cell culture system to study tumour--stroma interactions in non-small cell lung cancer cells.
PLoS One. 2014 Mar 24;9(3):e92511. doi: 10.1371/journal.pone.0092511. eCollection 2014.
9
LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5136-41. doi: 10.1073/pnas.0911220107. Epub 2010 Mar 1.
10
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19503-8. doi: 10.1073/pnas.0905056106. Epub 2009 Oct 22.
本文引用的文献
1
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Cancer Res. 2002 Jul 15;62(14):4132-41.
2
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Cancer Res. 2002 Jun 1;62(11):3151-8.
3
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
J Clin Oncol. 2002 Feb 1;20(3):719-26. doi: 10.1200/JCO.2002.20.3.719.
4
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7. doi: 10.1093/jnci/93.24.1852.
5
6
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
Int J Cancer. 2001 Dec 15;94(6):774-82. doi: 10.1002/ijc.1557.
7
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Oncogene. 2001 Nov 8;20(51):7551-62. doi: 10.1038/sj.onc.1204964.
8
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Cancer Res. 2001 Oct 1;61(19):7184-8.
9
10
ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini.
Nat Cell Biol. 2001 Sep;3(9):785-92. doi: 10.1038/ncb0901-785.
Zotero 插件